https://www.selleckchem.com/products/bda-366.html
Inflammation may be an important factor contributing to the progression of Eisenmenger syndrome (ES). The purpose of the current study was to characterize the inflammatory profile in ES patients and compare measures to reference values for congenital heart disease and pulmonary arterial hypertension (CHD-PAH); and investigate whether inflammatory markers are associated with other clinical markers in ES. Twenty-seven ES patients were prospectively selected and screened for systemic inflammatory markers, including interleukin (IL)-1β, tum